CCA Industries, Inc. (CAWW) research, news, and more from GeoInvesting

Company description

Mon, 17 Jul 2023 00:28:57 GMT

CCA Industries, Inc. manufactures and distributes health and beauty aid products in the United States and internationally. It offers oral health-care products under the Plus+White brand; skin-care products under the Sudden Change and Porcelana brand names; nail treatments under the brand name of Nutra Nail; medicated topical and shave gels under the Bikini Zone brand; depilatories under the Hair Off brand and; perfumes under the brand name of Sunset Cafe. The company markets its products to drug, food, and mass-merchandise retail chains; warehouse clubs; and wholesale beauty-aids through independent sales representatives and distributors, as well as through Internet. CCA Industries, Inc. was incorporated in 1983 and is based in Lyndhurst, New Jersey.

Research

Thu, 05 Mar 2026 16:37:47 GMT

Cca Industries, Inc. (OOTC:CAWW) ($0.51; $3.4M market cap) announced FY 2025 results:

Q4 2025 sales of $1.3 million vs. $1.6 million in the prior year
Q4 2025 EPS: loss of $(0.09) vs. loss of $(0.14) in the prior year
FY 2025 sales of $5,922,607 vs. $7,737,598 in the prior year
FY 2025 EPS: loss of $(0.10) vs. $(0.24) in the prior year

Management Commentary:

"Our 2025 results demonstrate meaningful progress. While revenue was lower than the prior year, much of the decline was intentional, reflecting our strategic decision to exit unprofitable products and focus on higher-margin opportunities. These actions have strengthened our resilience and diversified our business across both brick-and-mortar and online channels. Our contribution margin grew over 46% year-over-year, reflecting disciplined, strategic decisions, some of which were difficult but necessary. During 2025, supply-chain disruptions affected our two top-selling products and a key skincare ingredient, affecting our topline, but with new suppliers and increased inventory, stock levels returned to normal by the fourth quarter of fiscal 2025."

"At the end of January 2026, we sold the Lobe Miracle brand to generate capital to support our strategic focus on growing our flagship Plus White brand. This divestiture allows us to concentrate resources and accelerate investment in Plus White. In just the first month post-transaction, we are seeing over 50% top-line growth in Plus White compared to the prior year. We believe there is significant opportunity to expand our market share within the $8 billion teeth whitening category, and early indicators are promising."

"Our primary goal remains delivering profitable top-line growth, strengthening our cost structure, and positioning CCA for sustainable, long-term success. By balancing brick-and-mortar retail with online channels, we aim to reduce volatility and enhance long-term shareholder value.”

Our Quick Take:

CAWW is still in turnaround mode. They discontinued unprofitable products, which should increase their margins, and the recent divestment of their Lobe Miracle Brand allows them to focus on their growing Plus White brand, which has been growing at more than 50%.

Furthermore, CAWW hasn’t really been successful with its turnaround efforts as it has not been consistent with revenue growth and profitability yet. They kind of keep changing their plan because nothing has stuck. That’s minorly concerning, but not enough to change our desire to track the company.

CCA Industries, Inc. manufactures and distributes health and beauty products, including oral care, skincare, nail treatments, medicated gels, depilatories, and perfumes, sold under various brand names through retail chains, distributors, and online channels.

–

Research

Thu, 05 Feb 2026 16:35:23 GMT

CCA Industries, Inc. (OTC:CAWW) ($0.60; $4.0M market cap) announced sale of its Lobe Miracle brand:

Sold Lobe Miracle brand to Kingsway Pharmaceuticals, LLC for $1.2 million plus inventory at cost ( $217,886)
Proceeds will be used to pay down accounts payable and fund working capital
Company will maintain its existing line of credit
Strategic focus moving forward is on growth initiatives, especially the Plus White brand

Management Commentary

"This transaction positions CCA to accelerate the growth of our brands, with Plus White as a primary focus, within our portfolio. Over the past few years, we've made significant progress in streamlining operations, including relocating our third-party warehouse to Kansas City, which has reduced both warehousing and freight costs. While these improvements have strengthened our foundation, past losses had left us with a debt burden that limited our ability to invest in growth."

"With this strategic realignment, CCA now has the financial flexibility to prioritize initiatives that drive topline growth across our portfolio. Allowing us to invest strategically in advertising and to deliver innovative products to our customers. We are excited to embark on this new chapter, with a primary focus on expanding Plus White while also driving growth and value across all our brands."

Our Quick Take:

The sale of the Lobe Miracle brand for $1.4 million is a logical extension of their turnaround strategy. Consistent with prior asset sales, the proceeds will be used primarily to reduce near-term liabilities, restore financial flexibility, and invest in growth (something that they have not achieved yet).

While the narrative is good, this is similar to when we first came across the company; they had sold off an asset to help execute a growth turnaround plan. Obviously, this did not play out as planned, however, the first time it was to get the company out of debt and survive, this time around it seems it is to purely accelerate growth in other brand products.

CCA Industries, Inc. manufactures and distributes health and beauty products, including oral care, skincare, nail treatments, medicated gels, depilatories, and perfumes, sold under various brand names through retail chains, distributors, and online channels

Research

Thu, 16 Oct 2025 14:32:36 GMT

CCA Industries, Inc. (OTC:CAWW) ($0.51; $3.36M market cap) announced Q3 2025 results:

Q3 sales of $1.42 million vs. $1.76 million in the prior year
Q3 2025 EPS: $0.01 vs. $(0.06) in the prior year
Company resolved supply chain issues that disrupted production earlier in the year
New domestic and international suppliers secured, with improved cost structure
Revenue decline driven by intentional product exits to focus on higher-margin offerings

Christopher Dominello, Chief Executive Officer, commented, "The past year has been about strategy, discipline, and execution and the results speak for themselves. In just the first nine months of 2025, we’ve moved from an EBITDA loss to profitability, more than a $700,000 year-over-year improvement. This turnaround reflects not only financial progress but a fundamental strengthening of CCA’s business model. As we noted in our second-quarter earnings release, our company was impacted by supply chain issues that continued into the beginning of the fourth quarter. While all of our products are manufactured in the United States, certain components are sourced internationally, and delays in U.S. Customs clearance caused production disruptions. We have since secured new suppliers, including domestic vendors, and, as of October 2025, our inventory levels have returned to normal. Sales have rebounded accordingly, and we have negotiated lower costs with our new vendors - an improvement that should have a positive effect on future financial results."

Mr. Dominello continued, "I would also like to explain the primary reason for the reduced revenue year over year. While revenue for the first nine months of 2025 was lower year over year, much of that decline was intentional, driven by our decision to exit unprofitable products and focus on higher-margin opportunities. We’re building a more resilient and diversified company—balancing brick-and-mortar with online channels, reducing volatility, and enhancing long-term shareholder value. Looking ahead, our focus remains clear: to deliver profitable topline growth, strengthen our cost structure, and position CCA for sustainable, long-term success.”

Our Quick Take:

Admittedly, our expectations on the successful execution of the company’s turnaround is taking longer than we expected. However, we remain bullish on the company’s vision for growth and think the turnaround makes sense.

We’re still curious on how the company's penetration into CVS is shaping up. With that said, the 10-Q shows that CVS sales increased 50% ,year over year, but only at $110,000 in.

While we like the company as a very speculative long-term turnaround,we don’t have a good reading on when an inflection point may occur, however it appears it could be Q1 2026.

Research

Wed, 16 Jul 2025 04:00:00 GMT

CCA Industries, Inc. (OTC:CAWW) ($0.89; $5.88M market cap) announced Q2 2025 results:

Q2 2025 sales of $1,585,567 vs. $2,210,566 in the prior year
Q2 2025 EPS: $0.00 vs. ($0.00) in the prior year
Supply chain disruptions affected Q2 sales and are expected to continue into Q3.
EBITDA improved significantly: $68,677 in Q2 2025 vs. $1,831 in Q2 2024.

"The financial results for both the quarter and year to date as of May 31, 2025, shows how the tremendous efforts of reducing expenses and maximizing margins has now taken effect in producing profits. This has put the Company on a much more stable financial platform and will enable us to invest in our brands in order to turn our focus on growing sales. We did have some supply-chain issues that impacted sales in the second quarter, and we will be managing through some in the third quarter as well but feel confident they are short term issues." – Christopher Dominello, Chief Executive Officer

Our Quick Take:

Although small, it is nice to see the company maintain profitability, and exciting to think of what the new model will look like if management can get topline growing as they had stated as a 2025 goal.

Research

Wed, 16 Apr 2025 14:58:16 GMT

CCA Industries, Inc. (OTC: CAWW) ($0.79; $5.19M market cap) announced Q1 2025 results:

Q1 sales of $1.67 million vs. $2.13 million in the prior year
Q1 EPS of $0.00 vs. ($0.03) in the prior year
- Squeezes out small profit of $13,731
We’d like to understand what the company’s on-line marketing strategy entails, now that it’s abandoned selling to consumers on Amazon. Selling on-line was a big part of the company’s turnaround.
No mention of the information arbitrage we highlighted on 4/14/2025 regarding the leading competitor to the company’s new brain supplement product losing its ability to make claims that helped it build a $160 million brand.

Management Quotes:

"As we discussed in our fiscal 2024 earnings release, we were able to generate a positive EBITDA for the first quarter of 2025. The improvement in EBITDA over the first quarter of 2024, where we lost close to $300K, is substantial."

"Our expectation is that we will continue the trend of profitability for the foreseeable future."

"A primary reason for the reduction in revenue in the first quarter of 2025 vs the first quarter of 2024 was our strategic decision to cut out unprofitable sales in both retail and Amazon direct-to-consumer, and focus on bottom line gains."

"Again, we made many moves throughout 2024 that facilitated the turnaround, and we now look to grow topline in a more meaningful way in 2025. That will include investment spending behind brands we believe have sizable growth potential."

"As always, there will be challenges that arise, but this team has shown a track record of navigating those challenges and persevering. We appreciate the shareholders' support and patience as we look to build upon our momentum."

CCA Industries, Inc. manufactures and distributes health and beauty aid products in the United States and internationally.

Research

Mon, 14 Apr 2025 15:44:37 GMT

InfoArb Alert: CAWW's Competitive Moat May Have Just Deepened

Update to our original turnaround thesis on CCA Industries, Inc. (CAWW), published on March 18, 2024.
CCA Industries, Inc. manufactures and distributes health and beauty aid products in the United States and internationally.
Two new information arbitrage developments could enhance CAWW’s competitive position in the brain health supplement space.
Federal court ruling forces Prevagen (Quincy Bioscience) to strip “clinically proven” and cognitive benefit claims, removing a key marketing advantage from CAWW’s primary competitor.
Neutein by CAWW remains backed by a 90-day clinical trial with legitimate cognitive improvement data, strengthening its retail appeal and claim integrity.
Reviewing our April 2024 Open Forum clip that initially explored potential for a turnaround under the new CEO.

See The Full InfoArb Alert Here

Research

Mon, 03 Mar 2025 05:00:00 GMT

Cca Industries (OTC:CAWW) ($0.60; $4.5M market cap) announced Q4 2024 results

Sales of $1.6 million vs $2.1 million in the prior year
Non-GAAP net loss of $0.07 vs a net loss of $0.24 in the prior year

"I will start with the most important part first. As we wrap up the first quarter of 2025, we expect EBITDA to be profitable for the quarter. This is a substantial jump from the first quarter of 2024 where we lost close to $300K, and we expect that trend to continue in the quarters to come. As we said throughout 2024, it was a year of transition from a 100% brick-and-mortar retail company to a hybrid company through the growth of our online channels." Dominello continued, "We made many moves in 2024 that were hard decisions to make and others that were a bit easier, but we felt that all of them were the right ones for the future of CCA. The Company has made some significant restructuring changes to the business, including consolidating the three warehouses we were using into one new warehouse, which lowers our operating costs. We have already seen the results of that change in the first two months of fiscal 2025, with much lower warehouse and shipping costs, and cost of goods that decreased by approximately 5%. As I always say, we still face challenges, but we are still clear-eyed on what we need to do and where we are going. I look forward to sharing Q1 results in the very near future."

CCA Industries, Inc. manufactures and distributes health and beauty aid products in the United States and internationally.

Research

Thu, 17 Oct 2024 04:00:00 GMT

Cca Industries (OTC:CAWW) ($0.83; $5.6M market cap) - Yesterday we covered the CAWW’s Q3 2024 results.

The company issued a press release as a follow up. Based on the key takeaways from the release, listed below, there are some near-term challenges, particularly with the Neutein rollout at CVS, where lower-than-expected orders have impacted advertising efforts. However, progress with Walmart offers a potential growth opportunity, as the company has received a fast pass to present Neutein to Walmart buyers. On the profitability front, cost-cutting measures, including a 20% reduction in warehouse expenses and price increases across all brands, are expected to improve margins moving forward. While the company anticipates another loss in Q4, it remains optimistic about significant profitability improvements in 2025.

Challenges in Neutein CVS rollout:

“We have found challenges with the Neutein rollout at CVS. No easy way to say it other than it has been less than desirable. Their initial order was substantially below the norm – ordering approximately 2 units per store, whereas a normal order would be in the 4-6 units per store range. It is impossible to advertise in that situation because if your ad works, it moves the unit off the shelf, and then the shelf is empty for 2-3 weeks until replenished. We are working with CVS on ways to address this issue, and they have been responsive.”

Progress with Walmart:

“Also, regarding Neutein, we had a meeting in Chicago with senior members at Walmart and were awarded the coveted open-call fast pass to present Neutein to the Walmart buyer. Mike Singletary, Dr. Mike Roussell, and I attended this meeting that was held at Walmart's headquarters. Last week, we received a "New item Submission Form" from Walmart, which is an encouraging next step but certainly not the finish line and shouldn't be taken as such.”

Profitability:

Profitability can come from both expense reduction and/or revenue creation, and we have looked to do both.
Warehouse changes will lead to north of a 20% reduction in those sizable cost buckets which will certainly help profitability as we move forward.
Increasing prices across all brands

In summary:

“We are not out of the weeds yet but are very clear-eyed on what we need to do and where we are going. We have made great strides to date, and we feel our "go forward" strategy will take us to growth and profitability. The fourth quarter will likely also be a loss, but all the initiatives we are undertaking - and have completed - should lead to dramatic improvements in profitability in 2025 and beyond."

CCA Industries, Inc. manufactures and markets health and beauty aids, each under its individual brand name.

Research

Wed, 16 Oct 2024 15:14:25 GMT

Cca Industries (OTC:CAWW) ($0.83; $5.6M market cap) announced Q3 2024 results

Sales of $1.7 million vs $2.8 million in the prior year
Net loss of $0.06 vs a net loss of $0.06

Results via 10-Q only, we await the company’s press release for more color from management. Recall in the last release, the company mentioned

“Neutein, our brain health supplement launched at CVS in the second quarter of fiscal 2024, giving us pipeline orders in Q3. While we are encouraged with our achievements to date, we are still a work in progress. We have developed plans to grow both top and bottom line and are executing them during Q3, but the benefits will likely not be felt until Q4. These additional changes to increase our profitability will be announced later in the fourth quarter."

Research

Tue, 16 Jul 2024 15:54:51 GMT

Cca Industries (OTC:CAWW) ($0.82; $5.6M market cap) announced Q2 2024 results

Sales of $2.2 million vs $2.9 million in the prior year
Net loss of $0.00 vs a net loss of $0.02

“The EBITDA profit for the second quarter of fiscal 2024, though small, shows the beginning of our turn-around. As a reminder, we sold the Bikini Zone brand in the fourth quarter of fiscal 2023 which had sales of $3.2 million in the first half of fiscal 2023. Working to overcome that loss of revenue has been a focus, and our other brands have been increasing to fill the gap. Lobe Miracle, our ear protection brand, had increased gross sales by 31.6% year over year. Our Sudden Change skincare brand gross sales were up 20.3% year over year, and Neutein, our brain health supplement launched at CVS in the second quarter of fiscal 2024, giving us pipeline orders in Q3. While we are encouraged with our achievements to date, we are still a work in progress. We have developed plans to grow both top and bottom line and are executing them during Q3, but the benefits will likely not be felt until Q4. These additional changes to increase our profitability will be announced later in the fourth quarter."

Seems the turnaround story is progressing, we look forward to seeing what type of growth management sees come Q4.

Research

Wed, 29 May 2024 19:34:51 GMT

Cca Industries (OTC:CAWW) ($0.68; $4.5M market cap) announced that its Plus White brand was selected as the 2024 Oprah Daily’s Editor choice for teeth whitening.

“We believe it is the best teeth whitening kit on the market today, and obviously, Oprah Daily agrees. Our kit uses a hydrogen peroxide gel, similar to what dentists use for teeth whitening, but with a much more affordable price tag. You can find Plus White products for under $10! We thank Oprah Daily's Editor for reaching the same conclusion."

It’s good to see that the new CEO and marketing specialist , Christopher Dominello, is getting some things accomplished on the marketing and brand awareness front. Recall that he was apparently very instrumental in the turnaround of Nutrisystem.

Excerpt from our research report on CAWW:

During his eight-year tenure at Nutrisystem, Dominello successfully launched the brand internationally, and was a key member of the executive team that brought sales from $20M to $778M.

Interestingly, Oprah had been a key brand ambassador for Nutrisystem.

CCA Industries, Inc. manufactures and markets health and beauty aids, each under its individual brand name.

Research

Thu, 11 Apr 2024 16:58:09 GMT

Cca Industries (OTC:CAWW) ($0.68; $4.5M market cap) announced Q1 2024 results:

Sales of $2.1 million vs $2.4 million in the prior year
Should be noted, the brand Bikini Zone accounted for 25% of Q1 2023 sales and those sales are not included in Q1 2024 as the brand was sold in September 2023.
So sales of $2.1 vs $1.8 million on continuing operations
Net loss of $0.03 vs a net loss of $0.04

“We anticipated the loss for the first quarter of fiscal 2024 as we continued our turnaround efforts and 'set the table' for our latest news. We are pleased to announce that our brand, Neutein, will be in 3,420 CVS stores across the country beginning May 2024. We will begin an exciting marketing campaign for the brand featuring the NFL Hall of Fame football player Mike Singletary and other celebrities. We have also had interest from other retailers who want to consider carrying the brand. As we mentioned in previous press releases, this is the start of the Company's turnaround."

In October 2023, we discussed CAWW as a potential turnaround play. The company sold off some legacy assets, improved its balance sheet and began online sales to help drive growth for all its brands. In February 2024 we added CAWW to our Run To One Model Portfolio.

CAWW is a manufacturer and distributor of health and beauty aid products in the United States and internationally.

Research

Thu, 29 Feb 2024 15:28:15 GMT

Call To Action: Adding CAWW as a high risk Run To One Model Portfolio Holding

In October 2023, we discussed Cca Industries (OTC:CAWW) ($0.43; $2.8M market cap) as a potential turnaround play. The company sold off some legacy assets, improved its balance sheet and began online sales to help drive growth for all its brands.

Yesterday, the company reported its full year 2023 results, and we found that management is calling for a bullish 2024:

"We expect that Neutein, our brain health supplement, will begin shipping into retail in the second quarter of fiscal 2024. Our Amazon business, and other sites, continue to grow, with sales of nearly $6 million in fiscal 2023, an increase of 36% over the prior year. The Company installed new accounting software that gives management better visibility to our costs and financial results. We also enter 2024 with a stronger Balance Sheet than in previous years. The Company has been going through a series of years with losses, but we believe the shareholders will finally see the results of our turnaround efforts. "Our Company is now well positioned for growth and profitability in 2024."

Also notable is that the company’s on-line initiatives are gaining steam, with $6 million from Amazon.

“ Our Amazon business, and other sites, continue to grow, with sales of nearly $6 million in fiscal 2023, an increase of 36% over the prior year.”

Will continue to track this story to see if management can begin to deliver profitability. In the meantime, we are adding CAWW to our Run To One Model Portfolio.

Research

Tue, 10 Oct 2023 19:31:41 GMT

We are big on turnarounds and are in the process of determining whether one that just popped up on our radar, CCA Industries, Inc. (OTC:CAWW) (health and beauty products), is worth pursuing.

Management is making moves to improve the company’s balance sheet and income statement by selling assets and paying down debt to free up capital to initiate growth and marketing activities, as we explain later on in this email. This will be a case of seeing if CAWW can recapture its leadership position to help propel the stock back to its all time highs.

Turnarounds can offer great return potential because so many investors ignore them, thinking they are too risky.

CAWW is best known for its iconic Bikini Zone skin care and Plus White dental brands. Revenue topped out at $64 million in 2006, but has experienced a steady decline, now at $13 million.

This is a classic case of management getting too comfortable with legacy product lines, not innovating with new products and failing to adapt to new sales channels, like on-line.The stock has fallen from its high of about $12.00 in 2005 to $0,45 today.

The company’s lack of attention to shoring up their brand is evident in their unimpressive website presentation.

We’re going to see a lot more turnaround stocks in the current economic environment. The ones that give us the best chance for investing success are those of once great companies that still have industry presence and reputation.

**Updated 10/11/2023 for additional commetnary on CAWW

Cca Industries (OTC:CAWW) ($0.42; $18.7M market cap) ,a manufacturer and distributor of health and beauty aid products in the United States and internationally,we believe is worth a closer look due to a recent asset sale and reduction of debt.

On October 2nd, 2023, the company announced it sold its Bikini Zone brand for $2.5 million. The company will use the funds to pay off its outstanding credit line of $1.2 million, with the remaining funds used for working capital purposes.

The company has been losing money for the last several years and plans to use some of the funds to increase its internet advertising efforts.

We will continue to follow the company's steps to improve its balance sheet, reduce costs and focus on higher margin brands in their attempt to return the company to profitability.